Sapphire Therapeutics, Inc. Appoints New Director And Scientific Advisory Board

Published: Jan 17, 2006

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Jan. 17, 2006--Sapphire Therapeutics, Inc., a private biopharmaceutical company focused on cancer and metabolic disorders, today announced the addition of a new director and the appointment of a scientific advisory board (SAB). These appointments, along with recent management hires and promotions, are part of a controlled growth strategy to support two drugs in clinical development, advance the company's preclinical pipeline and in-license additional drug candidates.

Back to news